Topics

Celltrion contracts Lonza to manufacture autoimmune treatment Remsima

05:39 EDT 4 Oct 2019 | Generics and Biosimilars Initiative

South Korean biosimilars manufacturer Celltrion have announced a deal with Swiss contract manufacturing organisation (CMO) Lonza to produce its autoimmune biosimilar Remsima at a facility in Singapore.

Original Article: Celltrion contracts Lonza to manufacture autoimmune treatment Remsima

NEXT ARTICLE

More From BioPortfolio on "Celltrion contracts Lonza to manufacture autoimmune treatment Remsima"

Quick Search

Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...